Total Payments
$5,691
2024 Payments
$1,581
Companies
23
Transactions
313
Medicare Patients
95
Medicare Billing
$13,964
Payment Breakdown by Category
Food & Beverage$5,676 (99.7%)
Education$15.70 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,676 | 310 | 99.7% |
| Education | $15.70 | 3 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,296 | 73 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $927.70 | 55 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $716.99 | 51 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $619.63 | 36 | $0 (2024) |
| Alkermes, Inc. | $593.08 | 25 | $0 (2024) |
| Vanda Pharmaceuticals Inc. | $286.44 | 11 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $227.31 | 13 | $0 (2024) |
| Allergan, Inc. | $140.49 | 5 | $0 (2020) |
| Indivior Inc. | $134.90 | 6 | $0 (2023) |
| Lundbeck LLC | $127.17 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,581 | 81 | ABBVIE INC. ($402.95) |
| 2023 | $1,319 | 72 | ABBVIE INC. ($475.41) |
| 2022 | $892.49 | 55 | ABBVIE INC. ($198.73) |
| 2021 | $578.83 | 36 | AbbVie Inc. ($219.33) |
| 2020 | $431.65 | 20 | Allergan, Inc. ($140.49) |
| 2019 | $432.57 | 21 | Alkermes, Inc. ($161.63) |
| 2018 | $196.72 | 11 | Alkermes, Inc. ($89.64) |
| 2017 | $259.20 | 17 | Otsuka America Pharmaceutical, Inc. ($88.67) |
All Payment Transactions
313 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.34 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $20.30 | General |
| Category: CNS | ||||||
| 11/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $4.89 | General |
| Category: Neuroscience | ||||||
| 11/14/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $33.21 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $10.31 | General |
| Category: PSYCHIATRY | ||||||
| 11/12/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $6.29 | General |
| Category: Neurology | ||||||
| 11/05/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | Cash or cash equivalent | $65.26 | General |
| Category: SCHIZOPHRENIA | ||||||
| 11/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $32.12 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.79 | General |
| Category: NEUROSCIENCE | ||||||
| 10/31/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $7.04 | General |
| Category: Neuroscience | ||||||
| 10/29/2024 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $20.15 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 10/29/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $18.24 | General |
| Category: Psychiatry/Psychology | ||||||
| 10/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.55 | General |
| Category: NEUROSCIENCE | ||||||
| 10/17/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: Neuroscience | ||||||
| 10/16/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $12.97 | General |
| Category: PSYCHIATRY | ||||||
| 10/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.31 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $27.86 | General |
| Category: CNS | ||||||
| 10/01/2024 | Noven Therapeutics, LLC | Secuado (Drug) | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: CNS Psychiatry | ||||||
| 09/12/2024 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $22.47 | General |
| Category: CNS | ||||||
| 09/10/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.60 | General |
| Category: NEUROSCIENCE | ||||||
| 09/03/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: PSYCHIATRY | ||||||
| 08/29/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: Central Nervous System | ||||||
| 08/27/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $32.50 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 17 | 66 | $7,230 | $1,869 |
| 2022 | 1 | 20 | 77 | $5,698 | $2,878 |
| 2021 | 1 | 29 | 129 | $9,546 | $5,496 |
| 2020 | 1 | 29 | 100 | $6,733 | $3,721 |
Total Patients
95
Total Services
372
Medicare Billing
$13,964
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 17 | 66 | $7,230 | $1,869 | 25.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 77 | $5,698 | $2,878 | 50.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 29 | 129 | $9,546 | $5,496 | 57.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 29 | 100 | $6,733 | $3,721 | 55.3% |
About Dr. James Menges, M.D
Dr. James Menges, M.D is a General Practice healthcare provider based in Gainesville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2007. The National Provider Identifier (NPI) number assigned to this provider is 1427277300.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Menges, M.D has received a total of $5,691 in payments from pharmaceutical and medical device companies, with $1,581 received in 2024. These payments were reported across 313 transactions from 23 companies. The most common payment nature is "Food and Beverage" ($5,676).
As a Medicare-enrolled provider, Menges has provided services to 95 Medicare beneficiaries, totaling 372 services with total Medicare billing of $13,964. Data is available for 4 years (2020–2023), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty General Practice
- Location Gainesville, FL
- Active Since 04/25/2007
- Last Updated 02/18/2025
- Taxonomy Code 208D00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1427277300
Products in Payments
- VRAYLAR (Drug) $1,437
- INVEGA SUSTENNA (Drug) $521.28
- ABILIFY MAINTENA (Drug) $367.24
- REXULTI (Drug) $346.63
- AUSTEDO (Drug) $313.81
- VIVITROL (Drug) $244.14
- ABILIFY ASIMTUFII (Drug) $241.40
- INGREZZA (Drug) $227.31
- UZEDY (Drug) $213.14
- Austedo XR (Drug) $190.04
- CAPLYTA (Drug) $185.23
- HETLIOZ (Drug) $168.95
- ARISTADA (Drug) $157.72
- Aristada 441 mg (Drug) $125.98
- TRINTELLIX (Drug) $111.84
- SUBLOCADE (Drug) $111.71
- NUEDEXTA (Drug) $102.77
- BRIXADI (Drug) $92.75
- FANAPT (Drug) $89.17
- SPRAVATO (Drug) $64.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
General Practice Doctors in Gainesville
Dr. Carlos Tan, M.d, M.D
General Practice — Payments: $113,090
General Practice $113,090
Dr. Faline Phucas Davenport
General Practice — Payments: $22,806
General Practice $22,806
Kelley Brummett, Dmd, DMD
General Practice — Payments: $15,511
General Practice $15,511
Dr. Jordan Webb, Dmd, DMD
General Practice — Payments: $12,732
General Practice $12,732
Mr. Robert Klassen, Md, MD
General Practice — Payments: $12,202
General Practice $12,202
Dr. Frances Tardy-Rivera, M.d, M.D
General Practice — Payments: $9,748
General Practice $9,748